Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0017638 (
glioma
)
30,880
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Glioma
is the most aggressive, commonly occurring brain tumor in adults. Long non-coding RNAs (lncRNAs) are among the gene expression regulators in cancer development. Previous research posited that the up-regulation of LncRNA TP73-AS1 (TP73-AS1) in
glioma
is linked to low survival rates. However, the precise LncRNA TP73-AS1 mechanism in
glioma
remains unknown. Herein, we found that TP73-AS1 was up-regulated in glioma and was associated with a dismal prognosis. The silencing of TP73-AS1 repressed the multiplication of
glioma
cells and caused cell death. Mechanistically, we identified that TP73-AS1 in
glioma
acts as a ceRNA by sequestering miR-103a from
GALNT7
. Further, the results of this study revealed a reciprocal expression between TP73-AS1 and miR-103a, and a positive regulation between TP73-AS1 and
GALNT7
, validating the identified mechanism. Besides, luciferase reporter assay identified miR-103a as the direct binding site of both TP73-AS1 and
GALNT7
. Moreover, the findings of CCK-8 and colony-formation assays indicated that exogenous expression of
GALNT7
reversed TP73-AS1-induced division inhibition of
glioma
cells. Altogether, our results established that TP73-AS1 facilitates the progression of
glioma
through competing for endogenous RNA (ceRNA) in a TP73-AS1/miR-103a/
GALNT7
loop.
...
PMID:Long non-coding RNA TP73-AS1 contributes to glioma tumorigenesis by sponging the miR-103a/GALNT7 pathway. 3241 2